November 22nd 2024
Your daily dose of the clinical news you may have missed.
Despite Pfizer's high-profile drug failure, boosting HDL still a key heart-disease strategy
December 20th 2006Despite Pfizer's high-profile drug failure, boosting HDL still a key heart-disease strategy. Several drugs in development use various mechanisms to raise levels of "good cholesterol." Meanwhile, physicians can do plenty right now to raise patients' HDL levels.
New York City Bans Artificial Trans Fats in Restaurants
December 6th 2006NEW YORK -- The action by this city's Board of Health to ban the use of artificial trans fats in restaurants, ranging from pizzerias and delis to bakeries and upscale restaurants, could have fallout for mouths and lipid levels across the nation.
Man With GI Symptoms and Weight Loss Attributable to Primary Duodenal Adenocarcinoma
December 1st 2006A 71-year-old man presents with a2-week history of early satiety, decreasedappetite, postprandial nauseaand vomiting, jaundice, dark urine,acholic stools, and generalized pruritus.In addition, he reports a 4.5-kg(10-lb) weight loss within the past2 months.
Chest Film Clinic: What caused this man's dyspnea, chest pain, and atrial fibrillation?
December 1st 2006A 52-year-old man presented to his primary care physician with shortness of breath for 5 days, right-sided lower thoracic back pain, and dry cough. The patient was a 15-pack-year cigarette smoker who had emigrated from China to the United States in 1989. He had no significant history of occupational exposure or tuberculosis. He had no significant weight loss, and his past medical history was otherwise unremarkable.
Zenker Diverticulum in a 72-Year-Old Man
December 1st 2006A 72-year-old man was evaluated for worsening dysphagia and weight loss. The dysphagia had been intermittent for 20 years, but in the past year it had begun to occur daily. He regurgitated food after every meal, often many hours after ingestion.
A Theory Nixed for Why More Heft Means Less Premenopausal Breast Cancer
November 27th 2006BOSTON -- Cross ovulation and menstrual cycle patterns off the list for an explanation of why overweight women have less of a risk for premenopausal breast cancer, says a Harvard group. Instead, think hormonal for the perplexing protective effect.
AHA: Actos (pioglitazone) May Slow Progression of Atherosclerosis
November 14th 2006CHICAGO -- In a head-to-head trial with the sulfonylurea Amaryl (glimepiride), Actos (pioglitazone), a thiazolidinedione, appeared to slow the progression of a marker for atherosclerosis in patients with type 2 diabetes, researchers reported here.